Literature DB >> 7936190

Cathepsin G: localization in human cerebral cortex and generation of amyloidogenic fragments from the beta-amyloid precursor protein.

M J Savage1, M Iqbal, T Loh, S P Trusko, R Scott, R Siman.   

Abstract

Amyloid deposits in Alzheimer's disease, Down's syndrome and aged brain are composed largely of A beta protein, which is generated by proteolytic processing of beta-amyloid precursor protein. Proteases responsible for liberating the A beta protein from the precursor have not yet been identified. Here, we examined the ability of cathepsin G, a chymotrypsin-like protease, to cleave two protease substrates: (i) a fluorogenic hexapeptide, whose sequence spans the cleavage site in the precursor for generating the A beta NH2-terminus, and (ii) recombinant human beta-amyloid precursor protein purified from a baculovirus expression system. Unlike two other members of the chymotrypsin family, cathepsin G readily degraded the hexapeptide. Furthermore, cathepsin G cleaved the beta-amyloid precursor protein to generate several breakdown products, including a prominent 11,500 mol. wt fragment immunoreactive with antibodies directed against the COOH-terminus of the protein. This COOH-terminal fragment co-migrated using two-dimensional isoelectric focusing/sodium dodecyl sulfate-polyacrylamide gel electrophoresis with C-100, a recombinant COOH-terminal segment of the beta-amyloid precursor, whose NH2-terminus is one residue upstream of the NH2-terminus of the A beta domain. We also examined the localization of cathepsin G in human brain. The distribution of cathepsin G-containing cells was examined by immunohistochemistry in the temporal cortex of both Alzheimer's and aged control samples. Cathepsin G-like immunoreactivity was contained specifically within neutrophils. As visualized by double-labeling with antibodies to cathepsin G and Factor VIII, neutrophils were most frequently found within meningeal or cortical blood vessels. In addition, occasional neutrophils could be identified without an apparent vascular surround, in the brain parenchyma. By simultaneous labeling with antibodies to cathepsin G and A beta protein, neutrophils were also sometimes found associated with both parenchymal and vessel amyloid deposits; however, these associations were rare. These findings indicate that cathepsin G is capable of cleaving the beta-amyloid precursor protein to liberate the free NH2-terminus of the A beta protein and may have access to areas where this material is deposited in Alzheimer's disease. However, since there is no physical association between neutrophils and deposited amyloid and no increase in the number of neutrophils in an Alzheimer's brain, cathepsin G seems to be an unlikely mediator of amyloid deposition in this disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7936190     DOI: 10.1016/0306-4522(94)90490-1

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  17 in total

1.  Amyloid deposition and advanced age fails to induce Alzheimer's type progression in a double knock-in mouse model.

Authors:  Gauri H Malthankar-Phatak; Yin-Guo Lin; Nicholas Giovannone; Robert Siman
Journal:  Aging Dis       Date:  2011-07-28       Impact factor: 6.745

2.  Synergistic effects of hypertension and aging on cognitive function and hippocampal expression of genes involved in β-amyloid generation and Alzheimer's disease.

Authors:  Anna Csiszar; Zsuzsanna Tucsek; Peter Toth; Danuta Sosnowska; Tripti Gautam; Akos Koller; Ferenc Deak; William E Sonntag; Zoltan Ungvari
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-08-16       Impact factor: 4.733

3.  Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester.

Authors:  M J Savage; S P Trusko; D S Howland; L R Pinsker; S Mistretta; A G Reaume; B D Greenberg; R Siman; R W Scott
Journal:  J Neurosci       Date:  1998-03-01       Impact factor: 6.167

4.  The 1.8 A crystal structure of human cathepsin G in complex with Suc-Val-Pro-PheP-(OPh)2: a Janus-faced proteinase with two opposite specificities.

Authors:  P Hof; I Mayr; R Huber; E Korzus; J Potempa; J Travis; J C Powers; W Bode
Journal:  EMBO J       Date:  1996-10-15       Impact factor: 11.598

5.  Combination therapy prevents amyloid-dependent and -independent structural changes.

Authors:  Gauri Malthankar-Phatak; Shane Poplawski; Nikhil Toraskar; Robert Siman
Journal:  Neurobiol Aging       Date:  2011-01-22       Impact factor: 4.673

6.  Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition.

Authors:  Mary J Savage; Yin-Guo Lin; John R Ciallella; Dorothy G Flood; Richard W Scott
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

7.  Neutrophils promote Alzheimer's disease-like pathology and cognitive decline via LFA-1 integrin.

Authors:  Elena Zenaro; Enrica Pietronigro; Vittorina Della Bianca; Gennj Piacentino; Laura Marongiu; Simona Budui; Ermanna Turano; Barbara Rossi; Stefano Angiari; Silvia Dusi; Alessio Montresor; Tommaso Carlucci; Sara Nanì; Gabriele Tosadori; Lucia Calciano; Daniele Catalucci; Giorgio Berton; Bruno Bonetti; Gabriela Constantin
Journal:  Nat Med       Date:  2015-07-27       Impact factor: 53.440

Review 8.  Imaging of Leukocyte Trafficking in Alzheimer's Disease.

Authors:  Enrica Pietronigro; Elena Zenaro; Gabriela Constantin
Journal:  Front Immunol       Date:  2016-02-15       Impact factor: 7.561

9.  The hypothesis that Helicobacter pylori predisposes to Alzheimer's disease is biologically plausible.

Authors:  Felice Contaldi; Federico Capuano; Andrea Fulgione; Riccardo Aiese Cigliano; Walter Sanseverino; Domenico Iannelli; Chiara Medaglia; Rosanna Capparelli
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

10.  The Role of Neutrophil Proteins on the Amyloid Beta-RAGE Axis.

Authors:  Amanda J Stock; Anne Kasus-Jacobi; Jonathan D Wren; Virginie H Sjoelund; Glenn D Prestwich; H Anne Pereira
Journal:  PLoS One       Date:  2016-09-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.